• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-K filed by Stryker Corporation

    5/20/26 4:21:47 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care
    Get the next $SYK alert in real time by email
    8-K
    STRYKER CORP false 0000310764 0000310764 2026-05-15 2026-05-15 0000310764 us-gaap:CommonStockMember 2026-05-15 2026-05-15 0000310764 syk:M2.125NotesDue20272Member 2026-05-15 2026-05-15 0000310764 syk:SeniorUnsecuredNotes0.250Due2024Member 2026-05-15 2026-05-15 0000310764 syk:M0.750NotesDue20291Member 2026-05-15 2026-05-15 0000310764 syk:SeniorUnsecuredNotes3.375Due2028Member 2026-05-15 2026-05-15 0000310764 syk:SeniorUnsecuredNotes0.750Due2029Member 2026-05-15 2026-05-15 0000310764 syk:SeniorUnsecuredNotes2.625Due2030Member 2026-05-15 2026-05-15 0000310764 syk:SeniorUnsecuredNotes1.000Due2031Member 2026-05-15 2026-05-15
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 15, 2026

     

     

     

    LOGO

    Stryker Corporation

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Michigan   001-13149   38-1239739
    (State or Other Jurisdiction
    of Incorporation)
     

    (Commission

    File Number)

      (IRS Employer
    Identification No.)

     

    1941 Stryker Way  
    Portage, Michigan   49002
    (Address of Principal Executive Offices)   (Zip Code)

    Registrant’s Telephone Number, Including Area Code: (269) 385-2600

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $.10 Par Value   SYK   New York Stock Exchange
    2.125% Notes due 2027   SYK27   New York Stock Exchange
    3.375% Notes due 2028   SYK28   New York Stock Exchange
    0.750% Notes due 2029   SYK29   New York Stock Exchange
    2.625% Notes due 2030   SYK30   New York Stock Exchange
    1.000% Notes due 2031   SYK31   New York Stock Exchange
    3.375% Notes due 2032   SYK32   New York Stock Exchange
    3.625% Notes due 2036   SYK36   New York Stock Exchange

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    Stryker Corporation (the “Company”) announced on May 20, 2026 that William E. Berry, Jr. has decided to retire from his role as Vice President, Chief Accounting Officer of the Company effective September 1, 2026 and that Emily Baculik, who currently serves as Vice President, Corporate Controller, will also serve as chief accounting officer of the Company effective September 1, 2026.

    There are no arrangements or understandings between Ms. Baculik and any person pursuant to which Ms. Baculik was selected as an officer, and no family relationships exist between Ms. Baculik and any director or executive officer of the Company. Ms. Baculik is not a party to any transaction to which the Company is or was a participant and in which Ms. Baculik has a direct or indirect material interest subject to disclosure under Item 404(a) of Regulation S-K.

    Biographical Information

    Ms. Baculik, age 46, has been Vice President, Corporate Controller at the Company since November 2024. Prior to that, she was Vice President, Finance for the Spine Division from September 2022 to November 2024 and Senior Director, Finance from June 2021 to September 2022. Ms. Baculik has more than 20 years of finance and accounting experience with publicly traded companies and has prior experience in external financial reporting, technical accounting, compliance and controllership at Eaton, Rockwell Collins, Ingersoll Rand and U.S. Steel. Ms. Baculik graduated from the University of Notre Dame with a bachelor’s degree in history and earned a master’s degree in accounting from The Ohio State University.

    Transition Agreement with Mr. Berry

    Mr. Berry has entered into a Transition Agreement with the Company pursuant to which he will continue to be employed as Advisor to the Chief Financial Officer from September 1, 2026 until August 15, 2027 (the “Advisory Period”). During the Advisory Period, Mr. Berry will continue to receive base salary at his current annual rate of $510,000, and he will continue to be eligible to receive a 2026 incentive bonus with a target bonus percentage of 50% of his annual salary subject to the terms of the applicable bonus plan. Mr. Berry will not be eligible for an annual incentive bonus or any prorated bonus for services provided during 2027. Mr. Berry’s outstanding equity awards will be governed under the existing terms and conditions of the underlying award agreements and applicable long-term incentive plan, and he will not be eligible to receive any new equity awards during the term of his Advisory Period.

    Letter Agreement with Ms. Baculik

    Pursuant to the letter agreement establishing Ms. Baculik’s compensation, Ms. Baculik’s annualized base salary rate will increase to $420,000 effective September 1, 2026. Ms. Baculik’s bonus target will be 45% of her annual base salary, prorated for 2026 based on the portion of the year that she serves as the chief accounting officer of the Company and determined based on the applicable plan terms. In addition, a recommendation will be made to the Compensation and Human Capital Committee of the Board of Directors of the Company to approve awards to Ms. Baculik under the Company’s long-term incentive plan in February 2027. The awards would have an aggregate target value equal to approximately $400,000, comprised of 50% stock options (vesting 20% on each of the first five anniversary dates of the grant date) and 50% restricted stock units (vesting in three equal installments over an approximate three-year period after the grant date).

    The summary descriptions of the Transition Agreement with Mr. Berry and the letter agreement with Ms. Baculik contained in this Current Report on Form 8-K do not purport to be complete and are qualified in their entirety by, and should be read in conjunction with, the complete text of such agreements that are filed as Exhibit 10.1 and 10.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.

     


    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits

     

    10.1    Transition Agreement, dated May 15, 2026, between Stryker Corporation and William E. Berry, Jr..
    10.2    Letter Agreement, dated May 15, 2026, between Stryker Corporation and Emily Baculik.
    104    The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

     


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        STRYKER CORPORATION
        (Registrant)
    Dated: May 20, 2026     By:  

    /s/ Tina S. French

        Name:   Tina S. French
        Title:   Corporate Secretary
    Get the next $SYK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SYK

    DatePrice TargetRatingAnalyst
    4/13/2026$410.00Outperform
    Leerink Partners
    2/20/2026Outperform
    William Blair
    1/27/2026$387.00Hold
    TD Cowen
    1/6/2026$418.00Mkt Perform → Outperform
    Raymond James
    12/19/2025$440.00Mkt Perform → Mkt Outperform
    Citizens JMP
    9/18/2025$420.00Neutral
    Rothschild & Co Redburn
    2/26/2025$450.00Buy
    Citigroup
    12/2/2024$370.00 → $445.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $SYK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and COO Stiles Spencer S gifted 1,607 shares, decreasing direct ownership by 2% to 76,027 units (SEC Form 4)

    4 - STRYKER CORP (0000310764) (Issuer)

    6/2/26 4:24:03 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    VP, Chief Legal Officer Fletcher Robert S sold $1,394,409 worth of shares (4,544 units at $306.87) as part of a pre-agreed trading plan, decreasing direct ownership by 30% to 10,582 units (SEC Form 4)

    4 - STRYKER CORP (0000310764) (Issuer)

    5/29/26 4:59:21 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Director Stryker Ronda E sold $96,792,669 worth of shares (310,000 units at $312.23) (SEC Form 4)

    4 - STRYKER CORP (0000310764) (Issuer)

    5/28/26 5:22:36 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Stryker launches TPX HD® power tool, supporting demanding orthopaedic procedures

    PORTAGE, Mich., June 2, 2026 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced the launch of its TPX HD, a premium small bone power tool designed to support performance, control and ergonomics in a wide range of challenging orthopaedic procedures such as total joint revisions, minimally invasive surgery and oral maxillofacial procedures. "Revision procedures are some of the most demanding cases surgeons face, especially when metal cutting is involved," said Mike Carlin, president of Stryker's Ortho Tech division. "TPX HD was designed with tho

    6/2/26 9:03:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Stryker Launches Pangea Plating System and Completes First Case in Europe

    Stryker (NYSE:SYK), a global leader in medical technologies, announced today the European launch of its Pangea Plating System, a plating platform for the treatment of a wide range of fracture patterns. Prof. Alex Trompeter, design surgeon and orthopaedic trauma surgeon, along with his team at St. George's University Hospital in London, completed the first clinical case in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525326817/en/Stryker's Pangea Plating System brings together thoughtfully designed plates and a streamlined instrumentation set, giving surgeons practical options when treating a range of fractures. "Pan

    5/26/26 2:10:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    BioStar Capital-Backed Amplitude Vascular Systems' $835M Acquisition by Stryker Reflects Strength of Michigan's Medtech Ecosystem

    Three companies with strong roots in the state are revolutionizing the treatment of cardiovascular disease through hydraulic lithotripsy technology BioStar Capital, a venture capital firm focused on transformative medical technologies, has announced a landmark pre-FDA exit of Amplitude Vascular Systems, Inc. (AVS), a medical technology company that created a next-generation hydraulic intravascular lithotripsy (IVL) platform to treat calcified peripheral arterial disease. Upon acquiring AVS for up to $835 million, Stryker (NYSE:SYK), a global leader in medical technologies, called the deal a milestone in the expansion of its peripheral vascular portfolio. All three companies have close t

    5/19/26 5:30:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Financials

    Live finance-specific insights

    View All

    Stryker completes acquisition of Amplitude Vascular Systems to add next-generation IVL technology to peripheral vascular portfolio

    Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK announced that it has completed the acquisition of Amplitude Vascular Systems, Inc. (AVS), a privately held medical technology company developing a next-generation intravascular lithotripsy (IVL) platform designed to treat complex peripheral arterial disease. "This acquisition is a significant milestone in expanding our peripheral vascular portfolio and enhancing our ability to address challenging arterial disease," said Kevin Lobo, Chair and CEO, Stryker. "By integrating AVS's innovative CO₂-generated pressure wave technology with Stryker's scale and resources, we are well-positioned to deliver solutions that support p

    5/7/26 4:05:00 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Stryker declares an $0.88 per share quarterly dividend

    Portage, Michigan, May 07, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.88 per share payable July 31, 2026, to shareholders of record at the close of business on June 30, 2026, representing an increase of 4.8% versus the prior year and unchanged from the previous quarter.  About Stryker Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 m

    5/7/26 8:00:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Stryker reports first quarter 2026 operating results

    Portage, Michigan, April 30, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2026: First Quarter Results Reported net sales increased 2.6% to $6.0 billionOrganic net sales increased 2.4%Reported operating income margin of 15.5%Adjusted operating income margin(1) contracted 180 bps to 21.1%Reported EPS increased 14.2% to $1.93 Adjusted EPS(1) decreased 8.5% to $2.60  First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acquisitions / Divestitures OrganicMedSurg and Neurotechnology        5.0        %         1.4        %         3.6        %         2.7        %         0.9        %Orthopaedics        

    4/30/26 4:05:00 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    SEC Filings

    View All

    SEC Form SD filed by Stryker Corporation

    SD - STRYKER CORP (0000310764) (Filer)

    5/22/26 10:27:54 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by Stryker Corporation

    8-K - STRYKER CORP (0000310764) (Filer)

    5/20/26 4:21:47 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Stryker Corporation

    10-Q - STRYKER CORP (0000310764) (Filer)

    5/11/26 11:10:33 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Leadership Updates

    Live Leadership Updates

    View All

    GE HealthCare appoints medtech leader Kevin Lobo to Board of Directors

    GE HealthCare (NASDAQ:GEHC) announced today the appointment of Kevin A. Lobo, Chair and Chief Executive Officer of Stryker Corporation (NYSE:SYK), to its Board of Directors effective March 13. Mr. Lobo brings more than 25 years of medical technology, operational, and financial leadership experience. His clinical expertise and track record of driving innovation and scaling global businesses make him well qualified to contribute to GE HealthCare's strategic priorities. "Kevin is a seasoned healthcare executive with a deep understanding of the medical technology landscape. His knowledge and insight will further strengthen our Board as we continue to build a more personalized, connected and s

    3/17/26 9:00:00 AM ET
    $GEHC
    $SYK
    Medical Electronics
    Health Care
    Medical/Dental Instruments

    Stryker showcases continued innovation across orthopaedics at AAOS 2026 Annual Meeting

    Evolving technologies and offerings reinforce commitment to shaping the future of orthopaedic care PORTAGE, Mich., March 3, 2026 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, showcases its commitment to innovation across orthopaedic specialties with the introduction of the newest additions to the Triathlon® Total Knee System, the expanded Mako SmartRobotics™ portfolio and continued evolution of the power tool portfolio at the American Academy of Orthopaedic Surgeons' (AAOS) 2026 Annual Meeting in New Orleans. Triathlon Gold: Building on the legacy

    3/3/26 8:00:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    Stryker showcases next generation of Mako SmartRobotics™ at AAOS 2025 Annual Meeting

    Latest technology offers more applications and innovation across more specialties MAHWAH, N.J., March 11, 2025 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, showcases the latest advancements in Mako SmartRobotics™ across hip, knee, spine and shoulder procedures at the American Academy of Orthopaedic Surgeons' (AAOS) 2025 Annual Meeting in San Diego. With over 1.5 million Mako procedures performed globally across 45 countries, Mako is a market-leading technology in orthopaedics. With the introduction of Mako Total Hip with Advanced Primary and Rev

    3/11/25 8:03:00 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Stryker with a new price target

    Leerink Partners initiated coverage of Stryker with a rating of Outperform and set a new price target of $410.00

    4/13/26 9:01:23 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    William Blair initiated coverage on Stryker

    William Blair initiated coverage of Stryker with a rating of Outperform

    2/20/26 8:25:36 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    TD Cowen resumed coverage on Stryker with a new price target

    TD Cowen resumed coverage of Stryker with a rating of Hold and set a new price target of $387.00

    1/27/26 8:50:06 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    $SYK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Stryker Corporation (Amendment)

    SC 13G/A - STRYKER CORP (0000310764) (Subject)

    2/12/24 10:18:54 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Stryker Corporation (Amendment)

    SC 13G/A - STRYKER CORP (0000310764) (Subject)

    2/14/23 12:37:55 PM ET
    $SYK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Stryker Corporation (Amendment)

    SC 13G/A - STRYKER CORP (0000310764) (Subject)

    2/10/23 9:18:16 AM ET
    $SYK
    Medical/Dental Instruments
    Health Care